Sutent

SUTENT is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery. SUTENT is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC). SUTENT is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec�) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec�). Gleevec is a registered trademark of Novartis AG. SUTENT is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery.
 
For more than 10 years, SUTENT has been a widely used therapy in the treatment of advanced renal cell carcinoma (RCC) and certain patients with gastrointestinal stromal tumor, or GIST.� In clinical trials involving patients with advanced RCC or GIST, SUTENT was shown to help slow the spread of cancer. Animal and laboratory tests suggest that SUTENT helps to keep 2 basic actions of cancer in check. These actions of cancer are proliferation and angiogenesis. SUTENT is not a cure, may not work the same way in every person, and not all patients will experience the same results.